The C-C chemokine receptor type 5 (CCR5) expressed on immune cells supports inflammatory responses by directing cells to the inflammation site. CCR5 is also a major coreceptor for macrophage tropic human immunodeficiency viruses (R5-HIV-1) and its variants can confer protection from HIV infection, making it an ideal candidate to target for therapy. We developed a stepwise protocol that differentiates induced pluripotent stem cells (iPSCs) from individuals homozygous for the CCR5Δ32 variant and healthy volunteers into myeloid lineage induced monocytes (iMono) and macrophages (iMac). By characterizing iMono and iMac against their primary counterparts, we demonstrated that CCR5Δ32 homozygous cells are endowed with similar pluripotent potential for self-renewal and differentiation as iPSC lines generated from non-variant individuals while also showing resistance to HIV infection. In conclusion, these cells are a platform to investigate CCR5 pathophysiology in HIV-positive and negative individuals and to help develop novel therapies.

Derived myeloid lineage induced pluripotent stem as a platform to study human C-C chemokine receptor type 5D32 homozygotes / G. Chen, F. Calcaterra, Y. Ma, X. Ping, E. Pontarini, D. Yang, F. Oriolo, Z. Yu, A. Cancellara, J. Mikulak, Y. Huang, S. Della Bella, Y. Liu, L. Biesecker, R. Harper, C. Dalgard, M. Boehm, D. Mavilio. - In: ISCIENCE. - ISSN 2589-0042. - 26:11(2023), pp. 108331.1-108331.21. [10.1016/j.isci.2023.108331]

Derived myeloid lineage induced pluripotent stem as a platform to study human C-C chemokine receptor type 5D32 homozygotes

F. Calcaterra
Co-primo
;
F. Oriolo;A. Cancellara;J. Mikulak;S. Della Bella;D. Mavilio
Co-ultimo
2023

Abstract

The C-C chemokine receptor type 5 (CCR5) expressed on immune cells supports inflammatory responses by directing cells to the inflammation site. CCR5 is also a major coreceptor for macrophage tropic human immunodeficiency viruses (R5-HIV-1) and its variants can confer protection from HIV infection, making it an ideal candidate to target for therapy. We developed a stepwise protocol that differentiates induced pluripotent stem cells (iPSCs) from individuals homozygous for the CCR5Δ32 variant and healthy volunteers into myeloid lineage induced monocytes (iMono) and macrophages (iMac). By characterizing iMono and iMac against their primary counterparts, we demonstrated that CCR5Δ32 homozygous cells are endowed with similar pluripotent potential for self-renewal and differentiation as iPSC lines generated from non-variant individuals while also showing resistance to HIV infection. In conclusion, these cells are a platform to investigate CCR5 pathophysiology in HIV-positive and negative individuals and to help develop novel therapies.
Immunology; Molecular biology; Stem cells research
Settore MED/46 - Scienze Tecniche di Medicina di Laboratorio
Settore MED/04 - Patologia Generale
Settore MED/50 - Scienze Tecniche Mediche Applicate
2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
iscience 2023.pdf

accesso aperto

Descrizione: Article
Tipologia: Publisher's version/PDF
Dimensione 5.57 MB
Formato Adobe PDF
5.57 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1030236
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact